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STEM CELL TOURISM
Recent years have seen a sharp increase in the number 
of patients, with a variety of diseases unresponsive 
to conventional medicines, travelling to various juris­
dictions across the world to receive unproven stem­cell 
based treatments – a phenomenon pejoratively described as ‘stem cell 
tourism’.[1] This raises significant ethical concerns, as patients receive 
treatments that are unproven, often unregulated, potentially harmful, 
and often fraudulent.[2] Although stem cell therapy (defined as ‘the use of 
stem cells for therapeutic purposes’[3] is largely still experimental, proven 
existing therapeutic applications for stem cells (based on clinical trials 
that have demonstrated the efficacy and safety of these applications) 
are those used for the treatment of blood or immunological disorders, 
with bone marrow (BM) derived haematopoietic stem cells (HSCs) having 
been routinely used for more than 50 years.[4]
Despite the existence of regulations governing research with 
human subjects, as well as medical malpractice and licensing laws 
in some jurisdictions, guidelines in general are not specific to 
stem cell therapy.[5] With increased attention following a number 
of adverse events resulting from some of these unfounded claims, 
the scientific community has begun to develop guidelines for 
researchers and physicians involved in the clinical translation of 
stem cell research. However, despite these efforts and international 
agreements aimed at addressing this gap,[6] not all accept or abide by 
these rules. The social media is used to advertise these ‘miracle’ cures 
as routine therapies and to entice ignorant and desperate patients. 
The proliferation of these unproven ‘therapies’, no doubt facilitated 
by weak regulatory frameworks, also raises serious concerns about 
the exploitation of desperate and vulnerable patients, the regulation 
of cell­based therapies generally, as well as the governance of 
healthcare professionals.[7] It also jeopardises legitimate and inno­
vative translational stem cell research, emphasising the need for 
a clear distinction between reckless and unproven ‘therapies’ and 
legitimate, innovative stem cell­based interventions.
Late in 2012, a South African (SA) neurosurgeon, Dr Andre 
Liebenberg, claimed to have succeeded in paving the way for 
repairing spinal cord injuries using therapeutic stem cell cloning, by 
removing 35 mm from the spinal cord of a quadriplegic man and 
injecting a ‘special’ matrix containing these cells into the defect.[8] It 
subsequently emerged that, at that time, neither the neurosurgeon, 
nor his partner, Dr Gert Jordaan, had obtained prior ethical approval, 
subjected their work to peer review, published any of their research, 
or secured approval from the Medicines Control Council.[8] Their 
research has since been published.[9] Questioned at the time by 
the country’s stem cell experts, this example, conducted as an 
experimental treatment with the informed consent of the patient, 
was made possible by the legal lacunae that created opportunities 
for the development of unethical and unregulated practices in the 
stem cell field.[8] This example is relevant as it also illustrates the fine 
balance between scientific soundness in medical advancement, 
and uncontrolled experimental treatments that abuse patient 
vulnerability and compromise patient safety.
The SA population is particularly vulnerable in this regard, as limited 
information is available to provide South Africans with relevant, reliable 
and accurate information with regard to current, future or potential 
stem cell treatments.[4] In addition, physicians and healthcare providers 
are not informed of recent developments on a global front in this 
regard, nor of the legal implication in the South African context.[4]
The purpose of this article is to provide an update on the SA legal 
position relating to stem cell therapy, by discussing relevant requirements 
contained in the Medicines and Related Substances Act and regulations, 
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as well as other relevant legislative provisions in regulating cell­based 
therapies, drawing strongly on recent international developments and 
case law in this field. The article concludes with recommendations aimed 
at improving the existing position.
Some ethical, legal and scientific issues 
relating to unproven stem cell treatments
Safety, efficacy and quality 
Unproven therapies generally fail to comply with relevant minimal 
ethical, scientific or medical standards of safety and efficacy which 
clinical trials set out to determine. An assessment of the balance 
between risks and benefits associated with the intervention is not 
undertaken, not to mention the absence of measures aimed at 
ensuring that patients (or participants) understand the key issues 
of the therapy, which includes a realistic description of prospective 
benefits, particularly in instances where an intervention has never 
been done before and patients’ hopes are high. 
Unproven ‘treatments’ or ‘therapies’, mostly experimental in nature, 
are marketed as being successful based on unreliable and anecdotal 
evidence, including self­reports from patients.[2] Post­treatment care 
is seldom provided and there is no follow­up monitoring of patients 
or reporting of adverse events.[1] In addition, patients are charged 
excessive amounts for the therapy, which is a departure from the 
accepted norm that a provider of an experimental treatment does not 
charge a patient for the treatment. 
Stem cell­based interventions are associated with medical risks, 
which may include tumour growth, immunological reactions, 
unexpected or unpredictable cell behaviour, as well as unknown 
long­term health consequences.[10] Producing and testing stem cells 
for quality in sufficient batches is another challenge. As transplanted 
stem cells remain in the bodies of patients for many years, side­effects 
and long­term safety should be determined. 
Evidence of safety should be determined through appropriate pre­
clinical studies in relevant animal models or through human studies 
involving similar cell­based interventions, with stricter requirements for 
safety where cells were manipulated ex vivo or were derived from induced 
pluripotent stem cells (iPSCs).[10] Medical trials involving experimental 
drugs may pose other complications, such as compensation claims 
for non­medical­related injuries, as was the focus of a recent landmark 
decision (the Roche[11] decision) in South Africa. Key principles of 
importance for this article emerging from the Roche judgment are that:
• Regulators are responsible for assessing and approving the nature 
of the compensation for research­related injuries when reviewing 
and approving a study. 
• Research participants are bound by the terms contained within the 
informed consent document approved by these regulators and any 
amendment thereto should be in writing and duly communicated to 
and noted by the regulator in order to be legally binding. 
• An adequate informed consent process that distinguishes between 
researchers and sponsors and the limitation of compensation must 
be implemented. 
• Delictual claims for research­related injuries will not succeed if a 
plaintiff has signed an informed consent document limiting his or 
her rights and which limits compensation.[11]
Ethical oversight and patient protection
Unproven stem cell ‘treatments’ are often not part of clinical trials; no 
independent ethics review by recognised institutional review boards 
or ethics committees takes place and the research is not published 
in peer­reviewed journals, which makes replication of the research 
impossible.[1] Treatments are often offered in countries where it is 
difficult to institute medical negligence actions.[1]
The National Health Act (NHA) stipulates that all health research 
which involves human participants requires an independent 
review by an accredited and registered research ethics committee. 
Institutions conducting health research (e.g. private institutions and 
universities) must have an ethics committee or have access to one 
which is registered and accredited by the National Health Research 
Ethics Council.[12]The composition and operating procedures of ethics 
committees are described in the Act.[13] It is of utmost importance that 
because of possible unforeseen consequences and long­term health 
risks to participants or patients, ongoing regulatory oversight, once 
ethics approval has been granted, takes place.
Procedures to obtain voluntary informed consent from patients 
signing up for unproven therapies are often inadequate. Informed 
consent should strive to eliminate any possible misconceptions 
regarding therapeutic efficacy of the treatment, which is unlikely in 
the case of unproven treatments. The source of the stem cells should 
also be disclosed, for example cells derived from human fetuses 
or human embryonic stem cells (hESCs), which some patients may 
object to on moral grounds. In the case of some unproven treatments, 
a variety of cell sources are used, some even including animal tissue.[4]
Where stem cell procedures are part of stem cell clinical trials, 
it is imperative that research ethics committees or institutional 
review boards consist of members with specific expertise in stem cell 
research and its clinical translation. Chapter 9 of the NHA sets out the 
requirements regarding research on or experimentation with human 
subjects, as well as those relating to health research ethics committees.
Patient autonomy 
It is trite that the ultimate decision to undergo or refuse a medical 
intervention is that of the patient and not the doctor.[14] This is 
also the case, if from the point of view of the medical profession, a 
patient’s refusal seems grossly unreasonable and might result in his 
or her death, and even if the medical practitioners involved take the 
view that disclosure of the risks and dangers in such circumstances is 
unnecessary or undesirable.[15] As far as the context of stem cell therapy 
is concerned, it should be noted that patient autonomy, derived 
from the right to self­determination embodied in section 12 of the 
Constitution[16] which refers to the right to bodily and psychological 
integrity, has been statutorily reinforced in the following sections of 
the NHA:[17] section 6 ‘User to have full knowledge’; section 7 ‘Consent 
of user’; section 8 ‘Participate in decisions’; section 11 ‘Health services 
for experimental and research purposes’ and section 71 ‘Research on or 
experimentation with human subjects’. In addition, section 16(1)(d) of 
the same Act provides that healthcare providers must inform patients 
of their right to refuse healthcare services, and that they need to explain 
the implications, risks and obligations attached to such refusal. 
Patient autonomy, however, is not absolute and will be limited, 
depending on the circumstances. For example, patient consent to illegal 
or grossly negligent procedures (e.g. wanton experimentation) will 
be regarded as contra bonos mores, in other words, against the legal 
convictions of society or public policy. The consent of a fugitive to plastic 
surgery to mask his identity in order to escape prosecution is an example 
of invalid consent.[15] Patient autonomy is furthermore tempered by the 
implementation of the principles of beneficence, non­maleficence, justice 
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and fairness, which, in the case of unproven therapies, may point to an 
obligation on the part of those providing the treatment to act in the best 
interests of the patient and not to cause harm. Registered healthcare 
providers who provide dangerous and unproven stem cell therapies may 
face disciplinary action from their respective professional bodies.[18] 
Distributive justice
The broad potential public benefit offered by stem cell research 
requires a consideration of difficult questions relating to social and 
distributive justice, in particular as far as access to these treatments 
is concerned. Patients in developing countries have limited access to 
cell therapy as a therapeutic option. Developing countries, such as 
SA, are facing many challenges in ensuring that basic medical services 
are established and maintained. The need for specialised forms of 
treatment, such as cell­based therapies, is therefore questioned.[19]
Regulation of stem cell treatments
International Society for Stem Cell Research 
(ISSCR)
The International Society for Stem Cell Research is an independent, 
non­profit organisation that represents more than 4 000 members 
of the stem cell research community. The ISSCR’s Guidelines for the 
Clinical Translation of Stem Cells,[20] compiled by a group of stem cell 
researchers, ethicists, clinicians and regulatory officials from thirteen 
countries, condemns unproven use of stem cells or their direct 
derivatives to patients outside of a clinical trial, particularly when 
patients have to pay for such services.[21] As a matter of professional 
ethics, scientists, healthcare and research institutions should not 
participate in such activities. In countries where unproven therapies 
are offered, the regulators should work to prevent the exploitation 
of patients and, where relevant, take disciplinary steps against those 
clinicians involved and close down the fraudulent clinics. The ISSCR 
guides individuals in making informed choices when contemplating 
a stem cell­based intervention either locally or abroad.[22] 
Professional ethical guidelines and medico-
ethical codes of conduct
The conduct of doctors and the practice of medicine are governed 
by existing international and several national medico­ethical codes of 
conduct. Among national medico­ethical codes, the most important 
are the rules of conduct of the Health Professions Council of South 
Africa (HPCSA) and the guidelines on ethics for medical research of 
the South African Medical Research Council (MRC). 
Some of the guidelines relevant to the provision of treatment 
which overlap with guidelines regarding research are the following:
• Guidelines for Good Practice in the Health Professions (HPCSA, booklet 
2):[23]  ‘A practitioner shall in the conduct and scope of his or her practice, 
use only – (a) a form of treatment, apparatus or health technology 
which is not secret and which is not claimed to be secret; and (b) an 
apparatus or health technology which proves upon investigation to 
be capable of fulfilling the claims made in regard to it’ (par 19).
• Guidelines on Overservicing, Perverse Incentives and related matters 
(HPCSA, booklet 5):[23] ‘Health care practitioners shall not […] provide 
a service or perform procedures […] on a patient that are neither 
indicated nor scientific or have been shown to be ineffective, 
harmful or inappropriate through evidence­based review’ (par 3.1.1).
• General Ethical Guidelines for Biotechnology Research (HPCSA, 
booklet 7),[23] which contains instructive guidelines on a range of 
activities in the context of biotechnology research, including stem 
cell research (but not its clinical translation).
• General Ethical Guidelines for Health Researchers (HPCSA, 
booklet 6):[23] ‘Health researchers should […] fully inform research 
participants about which aspects of medical care, if any, are related 
to health research, and clearly distinguish between therapeutic 
interventions and health research processes’ (par 6.6.4).
• Guidelines on Ethics for Medical Research (MRC, 2004),[24] which 
contain guidelines regarding research involving innovative 
therapy or intervention (par 5.10), as well as detailed guidelines 
regarding the conduct of clinical trials and the use of human tissue 
samples.
• Guidelines for Good Practice in the Conduct of Clinical Trials 
on Human Participants in South Africa (Department of Health, 
2006),[25] which address general ethical issues with regard to clinical 
trials involving human participants.
Scientific experimentation and clinical trials, be they therapeutic or 
non­therapeutic, or beneficial to the patient or beneficial to others, 
are legally permissible provided they conform to the fundamental 
principles of informed consent to treatment, emergency treatment, 
the duty of reasonable care and with considerations of public policy 
in the particular circumstances.[26] Should an action for damages or a 
criminal charge flowing from harm allegedly suffered in consequence 
of improper or unacceptable experimentation arise, courts will be 
guided by the relevant ethical guidelines, such as those referred 
to above, as well as generally acknowledged international codes 
and declarations on human experimentation and a wide range of 
international declarations on human rights in general.[26]
Statutory framework
The registration of medicines in South Africa is governed by 
the provisions and requirements of the Medicines and Related 
Substances Control Act[27] (MRSCA). The aim of the Medicines Control 
Council (MCC), a statutory body established in terms of the MRSCA, 
is to protect and safeguard the public by ensuring that all medicines 
sold and used in SA are safe, therapeutically effective and that these 
medicines meet relevant and acceptable standards of quality.[28] 
The MCC’s Guidelines for the Registration of Medicines: General 
Information[29] aim to assist applicants in the preparation of 
documentation for the registration of medicines for human use.[30] 
Legislation requires that the MCC shall register every medicine 
before it may be sold or marketed.[31] An application for the 
registration of a medicine should therefore be submitted for 
evaluation and approval.  
The nature of a stem cell therapy is unique and different from 
conventional medicines. It may include characteristics and components 
of a ‘health service’, which include medical treatment,[32] ‘therapeutic’ 
or ‘non­therapeutic research’,[33] or ‘health services for experimental or 
research purposes, as described in the NHA.[34] Each of these has different 
legal and ethical considerations,[34] depending on whether one views 
cell­based therapy as a form of medical treatment, experimental research 
or medicine.[35] Stem cells used in HSC transplantation, essentially a 
stem cell intervention in existence for some decades as part of the 
treatment for certain haematological cancers and other disorders, are 
not registered with the MCC as a medicine, but an HSC transplantation 
requires, in addition to the written informed consent of the persons from 
whom the cells are removed, ministerial authorisation. [36]
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The MCC prohibits the sale of medicine which is subject to registration 
but not registered.[37] An exception would be where such medicine 
is compounded in the course of the person carrying on of his or her 
profession by inter alia a medical practitioner for a particular patient, ‘in 
a quantity not greater than that required for treatment as determined 
by the medical practitioner’[38] A particular substance must be used 
relatively widely for therapeutic purposes and not only on a ‘single 
occasion’ in order for the substance to qualify as a ‘medicine’ in terms 
of the Medicines Act.[39]
The Medicines and Related Substances Control Act (MRSCA) 
defines a medicine as:
‘any substance or mixture of substances used or purporting to be suitable 
for use or manufactured or sold for use in – 
(a) the diagnosis, treatment, mitigation, modification or prevention of disease, 
abnormal physical or mental state or the symptoms thereof in man; or 
(b) restoring, correcting or modifying any somatic or psychic or organic 
function in man, and includes any veterinary medicine.’[40]
Biological medicines, a highly specialised class or type of medicine, 
produced using living organisms, are complex protein structures 
typically much larger than traditional chemical medicines and are 
mostly administered by injection.[1] An example would be insulin 
used for the treatment of diabetes. Biological medicines are more 
advanced than conventional therapies and provide prescribers with 
enhanced tools for treating patients.[41] Though clinically effective, 
these medicines are very expensive in SA.[41]
The MRSCA does not define a biological medicine, but the guideline 
referred to above,[42] defines a biological medicine (categorised as a 
type of medicine) as follows:
‘A medicine where the active ingredient and/or key excipients have 
been derived from living organisms or tissues, or manufactured using 
a biological process. Biological medicines can be defined largely by 
reference to their method of manufacture (the biological process). These 
include inter alia medicines prepared from the following substrates: 
(i) Microbial cultures (fermentation); 
(ii) Plant or animal cell cultures (including those resulting from 
recombinant DNA or hybridoma techniques); 
(iii) Extraction from biological tissues; and 
(iv) Propagation of live agents in embryos or animals.
The living substrate may be genetically modified in a number of ways 
to provide the required active ingredient, including recombinant DNA 
technology or hybridoma techniques.
Biological Medicines include, but may not be limited to the following: 
(i) Plasma-derived products, e.g. clotting factors, immunosera, etc;
(ii) Vaccines;
(iii) Biotechnology-derived medicinal products (rDNA products) e.g. rHu-
antihemophilic factors, hormones, cytokines, enzymes, monoclonal 
antibodies, erythropoietins;
(iv) Human gene therapy.’ 
Based on ii and iii in the first section above, a stem cell product (or stem 
cell application) would therefore fall within the ambit of a biological 
medicine.[43] It will, however, be important to be more explicit about stem 
cells and their applications in any revision of these guidelines in the future.
Moreover, as far as the harvesting of the stem cells for therapeutic 
use is concerned, the harvesting, isolation, cryopreservation and any 
other activity in relation to these cells must comply with the relevant 
requirements stipulated in chapter 8 of the NHA[44] and relevant 
regulations, such as the regulations relating to the use of human 
biological material. An example of a present regulatory inconsistency 
that creates many practical obstacles in respect of routine procedures, 
(e.g. bone marrow transplantation), is that the requirement of ministerial 
authorisation for the removal of stem cells from living persons (the latter 
being the step preceding the use of the cells for therapeutic purposes) is 
mentioned in the Act itself, but not in the regulations (relating to the use 
of human biological material).[45] The Regulations relating to Stem Cell 
Banks[46] furthermore state that no person may release stem cells products 
for therapeutic use unless this activity is authorised in terms of section 
54 of the NHA and laboratory tests for certain transmissible diseases 
have been performed, where relevant.[47] In addition, no person may use 
stem cell products for therapeutic purposes unless he or she is registered 
with the department[48] and, among others, relevant written (and duly 
documented voluntary) consent has been obtained from the donor of 
the cells, even in the case of residual tissue, blood or blood products.[49]
Since the MRSCA requires that the MCC shall register every medicine 
before it may be sold and marketed, an application for the registration of a 
medicine should be submitted for evaluation and approval.[50] Applications 
for registration of a medicine for use in humans are divided into different 
types for the determination of fees and allocation to reviewers for 
evaluation.[51] As such, a biological medicine is one of the types of 
medicines applications. It is a legal requirement that data submitted for 
evaluation, by the applicant, should substantiate all claims and should 
meet the technical requirements of quality, safety and efficacy. The MCC 
refers to international guidelines to be read in conjunction with the SA 
guidelines. In particular, the MCC refers to the International Conference 
on Harmonization (ICH) of Technical Requirements for Registration of 
Pharmaceuticals for Human Use, the mission of which is to achieve greater 
harmonisation to ensure that safe, effective and high­quality medicines are 
developed and registered in the most resource­efficient manner.[52]
The ICH promotes public health, prevents unnecessary duplication of 
clinical trials in humans, and minimises the use of animal testing without 
compromising safety and effectiveness.[53] Therefore, any applicant 
for the registration of a medicine must ensure that the technical 
requirements of quality, safety and efficacy of the product for the 
purposes for which it is intended, have been met. After submission of the 
relevant administrative steps for the registration of a medicine (including 
a biological medicine),[54] these biological medicines (containing or 
derived from living materials) require primary evaluation by the Biological 
Medicines Committee, in addition to other committees of the MCC. The 
MCC may choose to accept, defer, or reject the application. Should 
the application be deferred, the applicant will be required to produce 
additional information and re­submit the application for approval. Once 
the application is accepted, the biological medicine is registered with the 
MCC and may be sold and marketed.[1]
Failure to register a stem cell therapy in the manner prescribed 
constitutes a contravention of section 14(1) of the MRSCA and 
hence an offence in terms of section 29, punishable by a fine or 
imprisonment of a period not exceeding 10 years.[55]
Conclusion
The brief discussion of the relevant regulatory framework, as well as some 
of the attendant legal, ethical and scientific concerns and complexities, 
points to a need for an unambiguous and coherent legal framework for the 
regulation of cell therapy. This is borne out by the rise in unproven therapies 
globally. The unique nature of cell therapy makes the conventional 
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medicines regulatory model a difficult fit for the proper legal regulation of 
this fast evolving and dynamic therapeutic field. Close scrutiny of chapter 8 
of the NHA, including regulations promulgated in terms of the Act relevant 
to stem cell research and therapy, is required, to close any regulatory gaps 
that may facilitate the promotion of unproven cell therapies. Inconsistent 
or conflicting statutory provisions, regulations and guidelines governing 
both research and clinical application may inadvertently expose vulnerable 
patients to possible exploitation by bogus stem cell therapy operators. 
As stated in the introduction, some physicians are already practising 
unregulated cell therapy in SA, with grave potential consequences. Access 
to novel therapies also raises pertinent issues regarding distributive justice 
and access to these treatments in a developing country where access 
to basic healthcare services is already severely compromised. Public 
educational programmes that provide the public with accurate and reliable 
information regarding legitimate and authentic existing cell therapies are 
critical, and should ideally include the provision of a platform (website or 
hot line) to which suspect stem cell activities could be reported.
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